Hormone Replacement Therapy at Med Spas and Wellness Clinics: What to Expect

Hormone replacement therapy (HRT) for menopause is prescription hormone treatment with estrogen, with or without a progestogen.

The FDA-approved products carry labels with named indications.

Premarin (conjugated estrogens) tablets, for example, are indicated for moderate-to-severe hot flashes due to menopause, moderate-to-severe vulvar and vaginal atrophy due to menopause, and prevention of postmenopausal osteoporosis, among other uses.

Note what that label does not list: Premarin's indicated uses do not include energy, libido, weight loss or "anti-aging." If a program markets hormone therapy for those goals, that use is not on the product's label.

Some med spas and wellness clinics sell hormone programs next to their aesthetic services.

Beyond the prescription itself, the pieces to pin down in any program are the consultation, the lab work, the prescribing and the follow-up — and, at some clinics, whether the preparations are compounded "bioidentical" pellets and creams.

Our search found no FDA-approved estradiol pellet, so the estradiol and female-testosterone pellets implanted at some clinics appear to be compounded preparations rather than FDA-approved products.

This guide covers menopausal hormone therapy only.

Gender-affirming hormone care is a separate field of medicine that we do not cover here.

The clearest published guidance comes from the Menopause Society (then NAMS), whose 2022 position statement says hormone therapy is the most effective treatment for hot flashes and genitourinary syndrome of menopause and prevents bone loss and fracture.

The same statement says risks depend on the type, dose, duration and route of therapy, the timing of initiation, and whether a progestogen is used.

On timing: for women younger than 60 or within 10 years of menopause who have no contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes and preventing bone loss.

Starting more than 10 years after menopause or after age 60 is less favorable, because the absolute risks of heart disease, stroke, blood clots and dementia are higher.

FDA's November 2025 labeling request moved in the same direction, asking that systemic product labels add consideration of starting hormone therapy for moderate-to-severe hot flashes in women under 60 or within 10 years of menopause.

For the transition years before menopause, see hormone replacement therapy for perimenopause.

The labels also name the flip side — the contraindications, the conditions where the product should not be used.

Premarin's label, for example, lists undiagnosed abnormal genital bleeding, current or past breast cancer (except selected metastatic cases), estrogen-dependent cancers, current or past blood clots (DVT/PE), stroke or heart attack, liver disease, and inherited clotting disorders.

A prescriber needs your history to screen for those.

Candidacy is not automatic at the other end either.

For vaginal dryness and genitourinary symptoms alone, the 2022 statement recommends low-dose vaginal estrogen or other therapies, such as vaginal DHEA or oral ospemifene, when over-the-counter products are not enough and systemic therapy is not otherwise indicated.

A full-body hormone program is not the only option on the menu.

Marketing names aside, two distinctions do most of the work.

The first is systemic versus vaginal: FDA's 2025 labeling request refers to "systemic" products as a group, and for vaginal symptoms alone the Menopause Society recommends low-dose vaginal estrogen or other therapies, such as vaginal DHEA or oral ospemifene.

The second is estrogen-alone versus estrogen plus a progestogen — the two arms the Women's Health Initiative tested, and one of the factors the Menopause Society says changes HRT's risk profile.

On dosage forms, our research documents two in detail.

Tablets: Premarin (conjugated estrogens) tablets are an FDA-approved menopausal hormone product with the indications described above.

Pellets: the picture is thinner.

The only FDA-approved hormone pellet our search found is Testopel — testosterone pellets, 75 mg each, for subcutaneous implantation — indicated for testosterone replacement in males with primary or hypogonadotropic hypogonadism.

We did not find an FDA-approved estradiol pellet; on that basis, the estradiol and female-testosterone pellets implanted at some clinics appear to be compounded preparations rather than FDA-approved products.

The National Academies went further, recommending that FDA's Pharmacy Compounding Advisory Committee consider all compounded hormone pellets as candidates for its "Difficult to Compound" list.

If the hormone in question is testosterone for a man, see our guide to TRT, which covers the label requirements, monitoring and pricing in detail.

We did not verify specific patch, cream, gel or injection products for menopause in this research, so this guide will not name approval details for those forms.

Any licensed provider can tell you which exact product they would use, and that product's label states its approved uses.

"Bioidentical" and "compounded" get used as if they were the same word, and they are not.

FDA has approved dozens of hormone therapy products — estradiol, progesterone and testosterone among them — reviewed for safety and efficacy.

An FDA-approved product can be bioidentical; what it is not is compounded.

Compounded "BHRT" blends are custom-compounded preparations and are not FDA-reviewed.

The review to know is the 2020 National Academies (NASEM) report commissioned by FDA.

It concluded there is insufficient evidence to support the clinical utility of compounded bioidentical hormone therapy for menopause or male hypogonadism symptoms, and recommended restricting its use.

It also noted that compounded hormone preparations are not required to demonstrate safety or effectiveness before dispensing, and estimated 26 to 33 million compounded hormone prescriptions a year, costing upwards of $2 billion.

Those figures describe the compounded hormone market overall — and they are reason enough to scrutinize the marketing before you pay for it.

Prescribing is the legal heart of any hormone program.

Our research did not find a federal rule naming who may prescribe HRT at a med spa or wellness clinic; who may prescribe — a physician (MD or DO), a nurse practitioner (NP) or a physician associate/assistant (PA) — and under what supervision is a state-law question.

Ask any clinic directly which clinician writes the prescription and how supervision works, and check your state's rules.

On labs: in the sources this research read — FDA drug labels and the abstract (not the full text) of the Menopause Society's 2022 position statement among them — we did not find a requirement for routine hormone blood levels to diagnose menopause or to set menopausal HRT doses.

We also did not confirm a required baseline lab panel for starting estrogen therapy.

That is not a claim that tests are useless; it means no label or society statement we read makes a particular panel a condition of treatment.

If a program presents a hormone or saliva panel as mandatory, ask which guideline requires it and what the results would change about your treatment.

Program structure is the other thing to pin down before you pay.

What happens at the first visit, who reviews the labs, who adjusts the dose over time, and what follow-up is included are all questions a straightforward program answers without prompting.

Get the answers in writing.

The risk picture starts with the label.

Premarin's label still states that the Women's Health Initiative estrogen-plus-progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism, heart attack and invasive breast cancer, and that the estrogen-alone substudy reported increased stroke and DVT.

The WHI itself randomized 27,347 postmenopausal women aged 50 to 79 (mean age 63) in 1993-1998 to estrogen plus progestin (median 5.6 years) or estrogen alone (median 7.2 years) versus placebo.

FDA says the estrogen-plus-progestin trial was stopped in 2002 after an increased risk of breast cancer was reported, and the estrogen-alone trial in 2004 for increased stroke risk and no heart-disease prevention.

FDA also notes that the participants averaged 63 years old — older than women typically starting HRT, since the average age at menopause in the US is 51.

The 18-year follow-up, published in JAMA in 2017, found no association between the hormone assignments and all-cause, cardiovascular or cancer mortality.

In November 2025, FDA announced it was initiating removal of the boxed-warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, while keeping the boxed warning on endometrial cancer for systemic estrogen-alone products.

The same labeling request removes the "lowest effective dose for the shortest time" recommendation from the boxed warning and, for systemic products, adds consideration of starting hormone therapy for moderate-to-severe hot flashes in women under 60 or within 10 years of menopause.

Cardiovascular and breast cancer warnings are retained elsewhere in the label.

Updates are rolling out product by product: Premarin's DailyMed label effective June 4, 2026 still carried a boxed warning for endometrial cancer, cardiovascular disorders, breast cancer and probable dementia.

Be careful with press-release numbers, too.

HHS's November 2025 press release claimed that women starting HRT within 10 years of menopause may reduce their risk of cardiovascular diseases "by as much as 50%," Alzheimer's disease by 35%, and bone fractures by 50 to 60%.

Those are HHS statements, not label claims, and HRT is not FDA-approved to prevent heart disease or dementia.

The Menopause Society's summary is the most useful frame for the whole question: HRT's risks depend on the type, dose, duration and route of therapy, the timing of initiation, and whether a progestogen is used.

Those are several variables at once, which is why the prescribing clinician and the follow-up plan matter as much as the product.

We could not confirm a national average price for hormone replacement therapy from a named survey or professional body, so this page will not quote one.

Any dollar figure a clinic gives you is that clinic's own price, and local prices belong to each provider.

What we can describe is the structure to price out.

Before you pay, ask what each of these pieces costs:

• The initial consultation.
• Lab work, and whether it repeats.
• The medication itself.
• An insertion visit, if you choose pellets — pellets are implanted under the skin (subcutaneously), so there is a procedure component.
• Follow-up appointments.

If the preparation would be compounded, a pharmacy is part of the chain — ask how its charge is billed.

What to compare when you price programs against each other: whether the hormone would be an FDA-approved product or a compounded preparation, which form you would use, how often labs and visits repeat, and whether the program is sold as a membership.

The National Academies sized the compounded market at 26 to 33 million prescriptions a year, upwards of $2 billion — figures for that market overall, not for any one clinic.

Two honest limits: our research found no reliable source on whether a given program is insurance-eligible, and no HSA or FSA rule for hormone programs, so ask your insurer and the dispensing pharmacy.

And do not compare a compounded program's package price with an FDA-approved product's cash price as if they were the same kind of number — they buy different things.

Because the product is a prescription drug, the provider question is mostly a prescribing question.

Before you put money down, get answers to these:

A few answers should give you pause: a guarantee of results; a pitch that compounded hormones are safer, more natural or better than FDA-approved options (the National Academies found no rigorous evidence for that); or a claim that HRT prevents heart disease or dementia — it is not FDA-approved for either.

Nothing on this page is a recommendation for or against hormone therapy.

The Menopause Society's timing framework, the label's contraindications and the risks above are the material to bring into a conversation with a licensed clinician who can see your full history.